Alithea Genomics, a pioneering biotech company specializing in scalable RNA sequencing solutions, today announced a new agreement with Revvity Inc. to broaden access to MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq solutions through Revvity’s global commercial network.
The collaboration brings together Alithea Genomics’ scalable high-throughput transcriptomics technologies with Revvity’s comprehensive drug discovery and screening portfolio, enabling researchers to integrate transcriptomic profiling into large-scale phenotypic and functional genomics workflows, unlocking richer biological insight at scale.
MERCURIUS™ DRUG-seq complements Revvity’s screening workflows by adding scalable 3′ mRNA expression profiling to phenotypic and perturbation-driven screening readouts. High-content imaging and cell painting approaches can reveal how cells respond to perturbations, while DRUG-seq helps characterize the gene expression changes associated with those responses.
MERCURIUS™ Total DRUG-seq expands these capabilities with full-length, total RNA-seq at screening scale, supporting pathway-level analysis, target hypothesis generation, and follow-up studies where transcript structure, isoforms, or broader RNA biotypes are important. “By collaborating with Revvity, we are significantly expanding global access to our MERCURIUS™ technologies and enabling researchers to combine scalable transcriptomics with advanced phenotypic and functional genomics workflows,” said Riccardo Dainese, CBO and Co-founder of Alithea Genomics.
“Revvity is focused on helping researchers build more complete discovery workflows by connecting phenotypic, imaging, and molecular readouts,” said Craig Monell, SVP Life Science Reagents at Revvity. “Adding MERCURIUS™ DRUG-seq and MERCURIUS™ Total DRUG-seq to our portfolio gives customers a scalable way to add transcriptomic context to screening studies, helping them prioritize hits, explore the mechanism of action, and generate richer datasets for downstream analysis.”
The collaboration reflects growing demand for scalable multi-omics approaches that generate large, high-quality datasets for modern drug discovery, including AI- and machine learning-enabled applications.
About Alithea Genomics
Alithea Genomics is a world leader in massively multiplexed RNA-seq solutions designed to accelerate high-throughput transcriptomics. Its proprietary MERCURIUS™ DRUG-seq and MERCURIUS™ BRB-seq technologies dramatically reduce the cost and complexity of generating large-scale RNA data, enabling breakthroughs in drug development, crop engineering, cosmetics, and beyond. Founded in 2020 at EPFL in Lausanne, Switzerland, Alithea Genomics has operations in Europe and the United States.
For more information, visit www.alitheagenomics.com
About Revvity
At Revvity, “impossible” is inspiration, and “can’t be done” is a call to action. Revvity provides health science solutions, technologies, expertise, and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what’s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics, and more.
With 2025 revenue of $2.9 billion and approximately 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia, and governments in more than 160 countries worldwide.
For more information, visit https://www.revvity.com/
For research use only. Not for use in diagnostic procedures.
Media Contacts
Alithea Genomics
Riccardo Dainese
Co-founder and CBO
rdainese@alitheagenomics.com
Revvity Health Sciences, Inc
Chet Murray
Sr. Manager Corporate Communications
Chet.Murray@revvity.com